학술논문
COST-EFFECTIVENESS OF PEMBROLIZUMAB AS AN ADJUVANT TREATMENT FOR ADULTS AND ADOLESCENTS AGED 12 YEARS AND OLDER WITH RESECTED STAGE IIB/ IIC MELANOMA IN FRANCE
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15244733